SCHEDULE 13G/A: BlackRock Discloses 16.7% Stake in STAAR Surgical Co. Through Latest SEC Filing

BlackRock, Inc. has filed an amended Schedule 13G, revealing its beneficial ownership of 16.7% of STAAR Surgical Co.'s common stock as of December 31, 2024.

Summary

• BlackRock, Inc. reported beneficial ownership of 8,222,301 shares of STAAR Surgical Co. common stock.
• This represents 16.7% of the total outstanding common stock of STAAR Surgical Co.
• The filing is an Amendment No. 17 to Schedule 13G, indicating a routine update to a previously reported stake.
• BlackRock holds sole voting power over 8,039,145 shares and sole dispositive power over 8,222,301 shares.
• No shared voting or dispositive power was reported.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• iShares Core S & P Small-Cap ETF, a subsidiary of BlackRock, is identified as having an interest of more than five percent of the total outstanding common stock.
• BlackRock Fund Advisors is also noted as beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The filing is a routine ownership disclosure by a major institutional investor, BlackRock, maintaining a significant stake. While not directly indicative of company performance, a large, passive institutional holding can be viewed as a vote of confidence, hence slightly positive.

Positives

• BlackRock, a prominent institutional investor, maintaining a significant 16.7% stake in STAAR Surgical Co. suggests continued confidence in the company.
• The declaration that the investment is held in the ordinary course of business indicates a passive, long-term investment strategy rather than an activist intent, which can be viewed positively by management.

Negatives

• No specific negative information regarding STAAR Surgical Co.'s operations or financial performance is disclosed in this ownership filing.

Risks

• The document, being a Schedule 13G, does not detail specific operational, financial, or strategic risks related to STAAR Surgical Co. It is solely an ownership disclosure.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially influencing investor sentiment and perceived stability.
• Management: Awareness of a large, passive institutional investor on the shareholder register, which typically implies stability rather than activist pressure.

Key Dates

Keywords

STAAR Surgical Co., BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake, ophthalmology, medical devices